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Abstract
A prominent J wave is encountered in a number of life-threatening cardiac arrhythmia syndromes, 
including the Brugada (BrS) and early repolarization (ERS) syndromes. BrS and ERS differ with 
respect to the magnitude and lead location of abnormal J waves and are thought to represent a 
continuous spectrum of phenotypic expression termed J wave syndromes. Despite two decades of 
intensive research, risk stratification and the approach to therapy of these two inherited cardiac 
arrhythmia syndromes are still undergoing rapid evolution. Our objective in this review is to 
provide an integrated synopsis of the clinical characteristics, risk stratifiers, as well as the 
molecular, ionic, cellular and genetic mechanisms underlying these two fascinating syndromes 
that have captured the interest and attention of the cardiology community in recent years.
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Introduction
A prominent J wave in humans has long been observed in the ECG in cases of 
hypothermia1-3 and hypercalcemia.4, 5 More recently, the presence of prominent J waves has 
been identified as a marker for a substrate capable of generating life-threatening ventricular 
arrhythmias.6 In humans, the J wave more commonly appears as a J point elevation, with 
part of the J wave buried inside the QRS. When greatly amplified, it can appear as an ST 
segment elevation, as in cases of Brugada syndrome.
An early repolarization (ER) pattern in the electrocardiogram (ECG), consisting of a distinct 
J wave or J point elevation, a notch or slur of the terminal part of the QRS and an ST 
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segment elevation (Figure 1), is generally found in healthy young males and has 
traditionally been viewed as benign.7, 8 This view was challenged by us in the late 1990s and 
early 2000s on the basis of experimental data showing that an ER pattern in the canine 
coronary-perfused wedge preparation predisposes to the development of polymorphic 
ventricular tachycardia and fibrillation (VT/VF).6, 9-11 Validation of this hypothesis was 
provided eight years later by Haïssaguerre et al.12 and Nam et al.13 These reports together 
with numerous additional case control and population-based studies provided clinical 
evidence of an increased prevalence of ER pattern, particularly in inferior and infero-lateral 
leads, among patients with a history of idiopathic ventricular fibrillation, thus confirming a 
link between ER pattern in the ECG and life-threatening cardiac arrhythmias. Terminology 
relative to ER has been a matter of confusion and contention. 14-16 A recent expert 
consensus report recommends that peak of an end QRS notch and/or the onset of an end 
QRS slur be designated as J(p) and that J(p) should exceed 0.1mV in ≥2 contiguous inferior 
and/or lateral leads of a standard 12-lead ECG for early repolarization to be present.17
The two principal forms of J wave syndrome
Two distinct forms of inherited J wave syndromes are recognized: Early repolarization 
syndrome (ERS) and Brugada syndrome (BrS). Both are associated with vulnerability to 
polymorphic ventricular tachycardia (VT) and ventricular fibrillation (VF) leading to sudden 
cardiac death6, 12, 13, 18 in young adults without apparent structural heart disease. J wave 
syndromes are characterized by J-point and ST-elevation in distinct ECG-leads. The J wave 
syndromes have also, although far less often, been associated with sudden infant death 
syndrome (SIDS).19-21 BrS is the right ventricular variant of hereditary J wave syndromes. 
The region most affected by the disease is the anterior right ventricular outflow tract. BrS 
patients display J-point and ST-segment elevation in the right precordial leads.22, 23
An early repolarization ECG-pattern (ERP) is characterized by a distinct J wave or J-point-
elevation, notch or slur of the terminal part of the QRS and ST-elevation in the lateral (type 
I), infero-lateral (type II) or in infero-lateral + anterior or right ventricular leads (type III). 
ERP can be observed in acquired conditions such as hypothermia or ischemia.6, 24, 25 When 
associated with VT/VF, it is referred to as early repolarization syndrome (ERS). Despite the 
different regional localization within the heart, BrS and ERS display several clinical 
similarities, suggesting similar pathophysiology (Table 1).10, 14, 26-28 Previous studies have 
pointed to different pathophysiological basis based on the observation that sodium channel 
blockers unmask or accentuate J wave manifestation in BrS, but reduces the amplitude in 
ERS.29 The recent study by Nakagawa et al., however, showed that J waves recorded using 
unipolar LV epicardial leads introduced into the left lateral coronary vein in ERS patients 
were indeed augmented, even though J waves recorded in the lateral precordial leads were 
diminished, due principally to engulfment of the surface J wave by the widened QRS.30 
Interestingly, the study of Kawata et al. showing an effect of pilsicainide to augment J waves 
and ST segment elevation in the right precordial leads, while reducing ER in the lateral leads 
in the same patient, actually provides support for a similar mechanism of ERS and BrS in 
light of the results advanced by Nakagawa and co-workers.29 Also in support of the notion 
that these ECG patterns and syndromes are closely related are reports of cases of ERS that at 
times transition to ERS plus BrS.31, 32
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ERS and BrS share a number of common clinical features (Table 1): Males are dominant in 
both syndromes: in the Brugada syndrome, the percentage of males involved ranges from 71 
to 80 % in Caucasians but as high as 94%-96% in Japanese.33, 34 Similarly, in the setting of 
ER pattern, males develop ventricular fibrillation in 60% of cases in the study of 
Haïssaguerre et al 12 but in a much higher percentage reported by Japanese investigators.29 
The patients with BrS or ERS may be totally asymptomatic until presenting with syncope 
and sudden cardiac arrest often due to ventricular fibrillation. The risk for development of 
VT/VF is dictated in large part by the ER subtype (Type I, II or III), as previously 
discussed.6 In both syndromes, the highest incidence of ventricular fibrillation or sudden 
cardiac death occurs in the third decade of life when testosterone levels peak in males.35 
Another important clinical feature of both syndromes is that J wave and associated ST 
segment elevation are accentuated during bradycardia or after pauses.36, 37 This may explain 
why ventricular fibrillation in both syndromes often occurs during sleep or at a low level of 
physical activities.29, 38
In addition to reports of SCD in otherwise healthy patients displaying an ER pattern, this 
ECG pattern has been associated with an increased arrhythmogenic risk and SCD in patients 
with acute myocardial infarction39, chronic coronary disease40, heart failure41 and 
hypothermia 24, 42
Genetics
BrS has been associated with mutations in 19 different genes (Table 2). To date more than 
300 BrS-related mutations in SCN5A have been described 14, 43, 44 Mutations in CACNA1C 
(Cav1.2), CACNB2b (Cavß2b) and CACNA2D1 (Cavα2δ) are found in approximately 13% 
of probands.45-48 Mutations in glycerol-3-phophate dehydrogenase 1-like enzyme gene 
(GPD1L), SCN1B (β1-subunit of Na channel), KCNE3 (MiRP2), SCN3B (β3-subunit of Na 
channel), KCNJ8 (Kir 6.1), KCND3 (Kv4.3), RANGRF (MOG1), SLMAP, ABCC9 
(SUR2A), (Navß2), PKP2 (Plakophillin-2), FGF12 (FHAF1), HEY2, and SEMA3A 
(Semaphorin) are more rare.49-5354-6153, 62-69 We recently reported an association of BrS 
with SCN10A, a neuronal sodium channel that co-associates with SCN5A, with a yield of 
16.7%.70 Mutations in these genes lead to loss of function in sodium channel current (INa) 
and calcium channel current (ICa), as well as to a gain of function in transient outward 
potassium current (Ito) or ATP-sensitive potassium current (IK-ATP). Mutations in KCNH2 
and KCNE5, although not causative, have been identified as capable of modulating the 
substrate for the development of BrS. Loss-of-function mutations in HCN4 causing a 
reduction in pacemaker current, If, can unmask BrS by reducing heart rate.71
The familial nature of the ER pattern has been demonstrated in a number of studies.72-74 The 
ER pattern and ERS have been associated with mutations in 7 genes. Consistent with the 
findings that IK-ATP activation can generate an ER pattern in canine ventricular wedge 
preparations, mutations in KCNJ8 and ABCC9, responsible for the pore forming and ATP-
sensing subunits of the IK-ATP channel, has been reported in a patients with ERS as 
well.49, 51, 75 Loss of function mutations in the α1, α2 and α2δ subunits of the cardiac L-
type calcium channel (CACNA1C, CACNB2, and CACNA2D1) have been uncovered in 
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patients with ERS45 as have mutations in SCN5A.76 We have also recently reported an 
association of SCN10A with ERS.70
A word of caution is appropriate here. It is important to recognize that a small fraction of 
identified genetic variants in the numerous genes associated with BrS and ERS have been 
examined using functional expression studies to establish causality or to establish a plausible 
contribution to pathogenesis. Only a handful have been studied in genetically engineered 
animal model and very few have been studied in native cardiac cells or in induced 
pluripotent stem cell-derived cardiac myocytes isolated from ERS and BrS patients. 
Computational strategies developed to predict the functional consequences of mutations are 
helpful, but these methods have not been rigorously tested. The lack of functional or 
biological validation of mutation effects remains the most severe limitation of genetic test 
interpretation as recently highlighted by Schwartz et al.77 This limitation is still more 
concerning in cases in which a susceptibility gene is identified on the basis of a single 
proband and with the absence of familial segregation data. Recent studies have suggested a 
more complex genetic background for BrS. Bezzina et al60 provided evidence that BrS is 
associated with common genetic variants suggesting a multigenic origin of the syndrome. 
Other authors, including Le Scouarnec et al 78 and Behr et al79, have questioned the impact 
of rare gene-variants, with the exception of SCN5A, in the pathogenesis of the synmdrome. 
These studies once again call for caution in the interpretation of genetic resutls as well as the 
need for genotype-phenotype correlation data and functional expression data before 
designating a rare variants as causative of the disease.
Ionic and Cellular Mechanisms
The J wave is inscribed as a consequence of a transmural voltage gradient caused by the 
presence of an action potential notch in epicardium but not endocardium, secondary to a 
transmural distribution of transient outward current (Ito).27
The cellular mechanisms underlying J wave syndromes have been mired in 
controversy.80, 81 Two principal hypotheses have been advanced in the case of BrS (Figure 
2): 1) The repolarization hypothesis maintains that an outward shift in the balance of 
currents in right ventricular epicardium leads to repolarization abnormalities resulting in the 
development of phase 2 reentry, which generates closely-coupled premature beats capable of 
precipitating VT/VF; 2) The depolarization hypothesis maintains that slow conduction in 
the right ventricular outflow tract plays a primary role in the development of the 
electrocardiographic and arrhythmic manifestations of the syndrome. Although these 
theories are not mutually exclusive and may indeed be synergistic, from the standpoint of 
appropriate therapy, correct assessment of the cellular pathophysiology is important.
The most compelling evidence in support of the depolarization hypothesis comes from a 
study by Nademanee et al.82 showing that radiofrequency (RF) ablation of epicardial sites 
displaying late potentials and fractionated bipolar electrograms (EGs) in the right ventricular 
outflow tract (RVOT) of BrS patients significantly reduced the arrhythmia-vulnerability and 
ECG-manifestation of the disease. These authors concluded that the late potential (LP) and 
fractionated electrogram activity are due to conduction delays within the RVOT and 
elimination of the sites of slow conduction is the basis for the ameliorative effect of ablation 
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therapy.82 In a direct test of this hypothesis, our group recently suggested an alternative 
cellular electrophysiological mechanism as the basis for late potentials and fractionated 
electrogram activity in the setting of BrS.83 As illustrated in Figure 3, when the genetic 
defects associated with BrS are pharmacologically mimicked in the coronary-perfused 
canine right ventricular wedge model of BrS, high frequency late potentials develop in the 
right ventricular (RV) epicardium secondary to concealed phase 2 reentry. At other sites, 
low-voltage fractionated electrogram activity develops due to regional desynchronization in 
the appearance of the second action potential upstroke, secondary to accentuation of the 
epicardial action potential notch. In no case was delayed conduction of the primary beat 
observed.
If late potentials and fractionated electrogram activity recorded from the RVOT do not 
reflect depolarization and conduction abnormalities, what is the basis for the ameliorative 
effect of RVOT ablation? Figure 4 illustrates that ablation of sites of phase 2 reentry in the 
canine ventricular wedge model of BrS markedly diminishes the manifestation of J waves 
and ST segment elevation and abolishes all arrhythmic activity. The data provide support for 
the hypothesis that ablation destroys the cells with the most prominent action potential 
notch, thus eliminating the cells responsible for the repolarization abnormalities that give 
rise to phase 2 reentry and VT/VF. These findings collectively lend strong support for the 
repolarization hypothesis. Also in support of this thesis is the congruence between BrS and 
ERS, which by virtue of its name is considered to be due to a repolarization defect.
Conduction delays are known to give rise to notching of the QRS complex. Although such 
notching often occurs on the rising phase of the QRS or during the middle of the descending 
phase, it can occur at the terminal portion of the QRS, thus masquerading as a J wave. 14, 84 
How then can we differentiate an end of QRS notch from a J wave? One method that we and 
others have previously suggested is to gauge the response to prematurity or to an increase in 
rate. Delayed conduction invariably becomes worse at faster rates or during premature beats 
thus leading to an accentuation of the notch, whereas repolarization defects are usually 
mitigated resulting in a diminution of the J wave at faster rates. Although typical J waves are 
usually accentuated with bradycardia or long pauses, the opposite has been described.85, 86 J 
waves are often seen in young males with no apparent structural heart diseases, whereas 
intra-ventricular conduction delay is often observed in older individuals or those with a 
history of myocardial infarction or cardiomyopathy. Figure 5 illustrates examples of both. 
The tachycardia-augmented notches (Figure 5D) can result in apparent “J” waves that are as 
tall or taller than 50% of the R wave85 and as such may be more reasonably characterized as 
an R’ due to intra-ventricular conduction delay.84 The prognostic value of a fragmented 
QRS has been demonstrated in BrS, 87, 88 although fragmentation of the QRS is not 
associated with increased risk in the absence of cardiac disease. 89 Factors that may aid in 
the differential diagnosis of J wave vs IVCD-mediated syndromes are summarized in Table 
4.
The ionic and cellular mechanisms underlying ERS were recently advanced in a report by 
Koncz and co-workers.90 The authors provided evidence in support of the hypothesis that, 
similar to the mechanism operative in BrS, an accentuation of transmural gradients, in this 
case across the LV wall, underlies the repolarization abnormalities responsible for ERS, 
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giving rise to J point elevation, distinct J waves, or slurring of the terminal part of the QRS 
(Figure 1). The repolarization defect is accentuated by cholinergic agonists and reduced by 
quinidine, isoproterenol, cilostazol and milrinone, accounting for the ability of these agents 
to reverse the repolarization abnormalities responsible for ERS. 90, 91 These authors also 
showed significantly higher intrinsic levels of Ito in the inferior LV, providing an 
explanation for the greater vulnerability of the inferior LV wall to VT/VF.90 The clinical 
translation of these experimental findings has been facilitated by the advent and 
implementation of electrocardiographic imaging (ECGI) by Rudy and co-workers. Using 
ECGI mapping, Ghosh et al. identified abnormally short activation-recovery intervals (ARI) 
in the inferior and lateral regions of LV and a marked dispersion of repolarization in support 
of regional accelerated repolarization.92 More recent studies involving ECGI mapping in an 
ERS patient during VF have demonstrated VF rotors anchored in the inferior-lateral left 
ventricular wall.15
Risk stratification
A great deal of effort has been devoted to assessment of risk for the development of life-
threatening arrhythmias. The incidental discovery of a J wave on routine screening should 
not be interpreted as a marker of “high risk” for SCD since the odds for this fatal disease is 
approximately 1:10,000.93 Rosso et al. indicated that the presence of a J wave on the ECG 
increases the probability of VF from 3.4:100,000 to 11:100,000.94, 95 However, careful 
attention should be paid to subjects with “high risk” ER or J waves. Table 3 presents the 
available data of studies designed to identify patients at high risk. Among these risk 
stratifiers, some are highly predictive, including: 1) history of cardiac events or syncope 
likely due to VT/VF, 2) pause-dependent augmentation of J waves, especially when 
accompanied by T wave inversion, and 3) prominent J waves in global leads including Type 
1 ST segment elevation in the right precordial leads. Fragmentation of the QRS, although 
predictive of cardiac events in the J wave syndromes, is non-specific in that it is associated 
with a high risk of sudden death in other cardiac arrhythmia syndromes.
In the case of ERS, the morphology of the ST segment is reported to be associated with 
increased arrhythmic risk. Tikkanen et al were the first to suggest that a horizontal or 
descending ST segments portends a higher risk for arrhythmic events and SCD.96 In 
contrast, an ER pattern with a rapidly ascending pattern, typically observed in healthy 
athletes, was associated with a relatively benign prognosis. Rosso et al. and Rollin et al. 
reported additional evidence linking a horizontal ST segment to an increased risk for SCD 
soon thereafter. 97, 98
In a recent review, Mahida and coworkers concluded that the presence of inferior or 
widespread J point elevation, a markedly elevated J point, a horizontal or descending ST 
segment, pause-dependent augmentation of the J wave amplitude, short coupled 
extrasystoles, and QRS notching predict progressively greater risk for SCD in patients 
presenting with syncope. 15
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Approaches to therapy
Implantation of an ICD is the mainstay of therapy for J wave syndrome patients presenting 
with aborted SCD or documented VT/VF with or without syncope (Class I 
recommendation). 99, 100 According to the 2013 HRS/EHRA/APHRS consensus statement, 
ICDs can be useful (Class IIa) in symptomatic BrS patients with Type I pattern, in whom 
syncope was likely caused by VT/VF and may be considered (Class IIb) in asymptomatic 
patients inducible by programmed electrical stimulation (PES).101 ICDs are not indicated in 
asymptomatic patients. There is no clear role for PES in patients with ERS.
Pacemaker therapy—Although arrhythmias and sudden cardiac death generally occur 
during sleep or at rest and have been associated with slow heart rates, a potential therapeutic 
role for cardiac pacing remains largely unexplored.102
Only a few case reports are available in the literature.103, 104
Radiofrequency Ablation Therapy—Nademanee et al.82 showed that radiofrequency 
(RF) ablation of epicardial sites displaying late potentials and fractionated bipolar 
electrograms (EGs) in the right ventricular outflow tract (RVOT) of BrS patients can 
significantly reduce arrhythmia-vulnerability and the ECG-manifestation of the disease. 
Ablation at these sites was reported to render VT/VF non-inducible and to normalize the 
Brugada ECG pattern in the majority of patients over a period of weeks or months. Long-
term follow-up (20±6months) showed no recurrent VT/VF with only 1 patient on medical 
therapy with amiodarone. Since then, case reports have been published in support of these 
effects.105 Ablation therapy can be life-saving in otherwise uncontrollable cases or cases in 
which ICD therapy is contraindicated. In the HRS/EHRA/APHRS expert consensus 
guideline, radiofrequency ablation is a Class IIb recommendation in BrS-patient with 
frequent appropriate ICD-shocks due to recurrent electrical storms.101 There are no clinical 
reports of ablation of the LV substrate in patients with ERS.
Pharmacologic approach to therapy
Approach to therapy of BrS—ICD implantation may not be a practical solution for 
infants and young children due to a high complication rate or for patients residing in regions 
of the world where an ICD is out of reach because of economic factors. A pharmacologic 
approach to therapy, based on a rebalancing of currents active during the early phases of the 
epicardial action potential in the right ventricle so as to reduce the magnitude of the action 
potential notch and/or restore the action potential dome, has been a focus of basic and 
clinical research in recent years. Table 5 lists the various pharmacologic agents thus far 
investigated. Antiarrhythmic agents such as amiodarone and β blockers have been shown to 
be ineffective. 106 Class IC antiarrhythmic drugs (such as flecainide and propafenone) and 
class IA agents, such as procainamide, are contraindicated because of their effects to unmask 
the Brugada syndrome and induce arrhythmogenesis. Disopyramide is a class IA 
antiarrhythmic that has been demonstrated to normalize ST segment elevation in some 
Brugada patients but to unmask the syndrome in others. 107
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Because the presence of a prominent transient outward current, Ito, is central to the 
mechanism underlying BrS and ERS, the most rationale approach to therapy, regardless of 
the ionic or genetic basis for the disease, is to partially inhibit Ito. Cardio-selective and Ito-
specific blockers are not currently available. 4-aminopyridine (4-AP) is an agent that is ion-
channel specific at low concentrations, but is not cardio-selective in that it inhibits Ito in the 
nervous system. Although it is effective in suppressing arrhythmogenesis in wedge models 
of the Brugada syndrome, 10 it is unlikely to be of clinical benefit because of neurally-
mediated and other side effects.
The only agent on the market in the United States and around the world with significant Ito 
blocking properties is quinidine. It is for this reason that we suggested in 1999 that this agent 
may be of therapeutic value in BrS.10, 108 Experimental studies have since shown quinidine 
to be effective in restoring the epicardial action potential dome, thus normalizing the ST 
segment and preventing phase 2 reentry and polymorphic VT in different experimental 
models of the Brugada syndrome, regardless of which pharmacologic agents were used to 
mimic BrS-phenotype. 10, 83, 109-111 Additionally, a recent experimental study suggests that 
quinidine, owing to its effect to block Ito, can exert a protective effect against hypothermia-
induced VT/VF in a J wave syndrome model.42 It is noteworthy that historically, quinidine 
was used to prevent ventricular fibrillation in patients who required hypothermia for surgical 
procedures. 111
Clinical evidence of the effectiveness of quinidine in normalizing ST segment elevation and 
or preventing arrhythmic events in patients with the BrS has been reported in numerous 
studies and case reports 112-126 The first prospective study describing the effects of 
quinidine to prevent inducible and spontaneous ventricular fibrillation (VF) was reported by 
Belhassen and coworkers.115 The results were consistent with those reported the same group 
in prior years 113, 127 and later by other investigators 128, 129. The data highlight the need for 
randomized clinical trials to assess the effectiveness of quinidine, preferably in patients with 
frequent events who have already received an ICD. Hermida et al. reported 76 % efficacy in 
prevention of VF induced by PES.128
Because of the GI side effects of high dose quinidine, low-dose quinidine (<600mg) has 
been suggested to be as a therapeutic option. Marquez et al. evaluated the clinical history of 
symptomatic patients with recurrent arrhythmias and frequent ICD discharges and reported 
that relatively low dose quinidine, as adjunctive therapy, completely prevented arrhythmias 
in 85 % of the patients (median follow-up of 4years).118.
In a more recent trial conducted at two French centers, 44 asymptomatic BrS patients with 
inducible VT/VF were enrolled (47 ± 10 years, 95% male).130 Of these, 34 (77%) were no 
longer inducible while treated with 600 mg/day hydroquinidine (HQ) for 6.2 ± 3 years. 
Among the 10 other patients (22%), who remained inducible and received ICD (Group PVS
+), none received appropriate therapy during a mean follow-up of 7.7 ± 2 years. The overall 
annual rate of arrhythmic events was 1.04%, without significant difference between 
inducibility under HQ. One-third of patients experienced device-related complications.
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A prospective registry of empiric quinidine for asymptomatic Brugada syndrome has been 
established. The study appears at the National Institutes of Health website 
(ClinicalTrials.gov) and can be accessed at http://clinicaltrials.gov/ct2/show/NCT00789165?
term_brugada&rank_2. Doses between 600 and 900 mg were recommended, if tolerated. 116
In the latest_HRS/EHRA/APHRS expert consensus statement, quinidine was given a class 
IIa recommendation in BrS patients who are qualified for an ICD but in whom hindering 
factors are present, IIa in ICD-patients with electrical storms, and IIb recommendation in 
asymptomatic BrS-patients displaying a spontaneous Type I ECG. 101
The development of a more cardio-selective and Ito-specific blocker would be a most 
welcome addition to the limited therapeutic armamentarium currently available to combat 
this disease. Agents that augment the L-type calcium channel current, such as β adrenergic 
agents like isoproterenol, denopamine or orciprenaline, are useful as well. 10, 121, 125, 131-133 
Isoproterenol, sometimes in combination with quinidine, has been utilized successfully to 
control VF storms and normalizing ST elevation particularly in 
children 113, 114, 125, 129, 134-141. 119, 142-146. The occurrence of spontaneous VF in patients 
with Brugada syndrome is often related to increases in vagal tone and correspondingly 
electrical storm is sometimes treatable by the increase of sympathetic tone via isoproterenol 
administration. In the latest HRS/EHRA/APHRS guideline, Isoprotereonol has a Class IIa 
recommendation for BrS patients presenting with electrical storms.101
Another promising pharmacologic approach is the administration of phosphodiesterase III 
inhibitor cilostazol 125, 132, 147, which normalizes the ST segment, most likely by 
augmenting calcium current (ICa) as well as by reducing Ito secondary to an increase in 
cAMP and heart rate.148 Other diverse effects of cilostazol in playing a role in its beneficial 
impact cannot be excluded. (e.g.: adenosine, NO, mitochondrial IKATP 149) Its efficacy in 
combination with bepridil in preventing VF-episodes was recently reported by Shinoharaet 
al.150 A case report describing the failure of cilostazol in the treatment of a BrS-patient is 
also available in the literature.151
Milrinone is another phosphodiesterase III inhibitor recently identified as a more potent 
alternative to cilostazol in suppressing ST elevation and arrhythmogenesis in an 
experimental model of BrS.83, 152 No clinical reports have appeared as yet.
Wenxin Keli, a traditional Chinese medicine (TCM), in addition to its actions to suppress 
atrial fibrillation by atrial-selective inhibition of INa-dependent parameters153, has recently 
been shown to inhibit Ito and thus to suppress polymorphic VT in experimental models of 
BrS when combined with low concentrations of quinidine (5 μM). 110 A recent study has 
also reported the effect of Wenxin Keli to suppress ischemia-induced ventricular 
arrhythmias.154
Agents that augment sodium channel current active during the early phases of the action 
potential, including bepridil and dimethyl lithospermate B (dmLSB), have been suggested to 
be of value in BrS. Bepridil has been reported to suppress VT/VF in several studies of 
patients with BrS.125, 155-157 The drug's action are thought to be mediated by: 1) inhibition 
of Ito; 2) augmentation of INa via upregulation of the channels158; and 3) prolongation of QT 
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interval at slow rates thus increasing the QT/RR slope.155, 157 Dimethyl lithospermate B, an 
extract of Danshen, a traditional Chinese herbal remedy, has been reported to slow 
inactivation of INa thus increasing INa during the early phases of the action potential (AP) 
and thus to suppress arrhythmogenesis in experimental models of BrS.159
Approach to therapy of ERS—It is not surprising that the approach to therapy of ERS is 
similar to that of BrS, since the mechanisms underlying the two syndromes are similar. 
Quinidine, phosphodiesterase III inhibitors and isoproterenol have all been shown to exert 
an ameliorative effect in preventing or quieting arrhythmias associated with ERS. 
Isoproterenol has been shown to be effective in quieting electrical storms developing in 
patients with either BrS125, 134 or ERS75. Isoproterenol acts by increasing ICa, thus leading 
to a reversal of repolarization abnormalities secondary to restoration of the epicardial action 
potential dome in experimental models of BrS 10, 109 and ERS 90.
The phosphodiesterase (PDE) III inhibitor cilostazol has been reported to reduce the ECG 
and arrhythmic manifestations of ERS.160 PDE inhibitors are known to activate ICa 
secondary to an increase in cAMP.132, 148, 161-165 The augmentation of ICa is thought to 
prevent arrhythmias associated with the J wave syndromes by reversing the repolarization 
defects and restoring electrical homogeneity across the ventricular wall secondary to 
restoration of the epicardial action potential dome in both BrS152 and ERS.42 Cilostazol has 
been hypothesized to also block Ito. Augmentation of ICa together with inhibition of Ito are 
expected to produce an inward shift in the balance of currents active during the early phases 
of the epicardial action potential that should be especially effective in suppressing J wave 
activity.
The effectiveness of bepridil in ERS has been reported in a single patient thus far.166
No clinical data are available regarding the effectiveness of radiofrequency (RF) ablation in 
the setting of ERS, despite the fact that low voltage fractionated electrogram activity and 
high frequency late potentials are observed in the LV in patients with ERS30 and in 
experimental models of ERS (Yoon and Antzelevitch, unpublished observation). Nakagawa 
et al.30 reported the results of a study in which they recorded epicardial electrograms 
directly from the left ventricle of patients diagnosed with ERS by introducing a multipolar 
catheter into the left lateral (marginal) coronary vein, anterior interventricular vein (AIV), 
and middle cardiac vein (MCV) via the coronary sinus. The authors reported late potentials 
in the bipolar electrograms recorded from the left ventricular (LV) epicardium of the ERS 
patients.30
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Figure 1. 
Mechanisms underlying the different manifestations of the early repolarization pattern in the 
ECG. Each panel shows transmembrane action potentials simultaneously recorded from the 
epicardial and endocardial regions of an arterially-perfused canine left ventricular wedge 
preparation together with a transmural ECG. Under the conditions indicated, the transmural 
voltage gradients created by the appearance of an action potential notch in epicardium but 
not endocardium gives rise to an elevated J wave onset, JO, (A),as distinct J wave (B), 
slurring to the terminal part of the QRS (C), a distinct J wave together with a ST elevation 
(D), a gigantic J wave appearing as an ST segment elevation (E). It is under these conditions 
that we see the development of polymorphic VT (F).Modified from 167, with permission.
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Figure 2. 
J wave Syndromes. Schematic depicts our working hypothesis that an outward shift in 
repolarizing current due to a decrease in sodium or calcium channel currents or an increase 
in Ito, IK-ATP, IKr or IK-ACh, or other outward currents can give rise to accentuated J waves 
associated with the BrS, Early Repolarization Syndrome and some forms of IVF. The 
particular phenotype depends on what part of the heart is principally affected and which ion 
channels are involved. Accentuation of thee J waves in the right ventricular outflow tract 
(RVOT) gives rise to BrS, whereas accentuation in the infero-lateral left ventricle (LV) 
gives rise to ERS.
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Figure 3. 
Heterogeneities in the appearance of the epicardial action potential second upstroke gives 
rise to fractionated epicardial electrogram (EG) activity and concealed phase 2 reentry gives 
rise to high frequency late potentials in the setting of Brugada syndrome (BrS). A: Shown 
are right precordial lead recordings, unipolar and bipolar EGs from the right ventricular 
outflow tract of a BrS patient. B: ECG, action potentials from endocardium (Endo) and two 
epicardial (Epi) sites, and a bipolar epicardial EG (Bipolar EG) all simultaneously recorded 
from a coronary-perfused right ventricular wedge preparation treated with the Ito agonist 
NS5806 (5 μM) and the calcium channel blocker verapamil (2 μM) to induce the Brugada 
phenotype. Basic cycle length=1000 ms. C: Bipolar EGs recorded from the epicardial and 
endocardial surfaces of the RVOT in a patient with BrS. The epicardial EG displays 
fractionated electrogram activity as well as a high frequency late potential late potential (130 
msec delay). D: Bipolar electrograms recorded from the epicardium and endocardium of a 
coronary-perfused wedge model of BrS, together with AP recordings from an endocardial 
and two epicardial sites and a transmural ECG. The clinical data are modified from 
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Nademanee et al.82 and the experimental data are from Szel and co-workers 83, with 
permission).
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Figure 4. 
Radiofrequency ablation of the epicardial surface abolishes the BrS ECG and suppresses 
arrhythmogenesis in coronary-perfused canine right ventricular wedge model of BrS. 
Transmembrane action potentials (AP) were simultaneously recorded from one endocardial 
(Endo) and two epicardial (Epi) sites together with epicardial bipolar electrograms (EG) and 
a transmural pseudo-ECG. The epicardial bipolar EGs were recorded at 10-1000 Hz 
bandwidth (black trace), and were simultaneously band-pass filtered at 30-200Hz, 50-200Hz 
and 100-200Hz (green traces). Column 1: Control. Column 2: Recorded 45 min after the 
addition of the Ito-agonist NS5806 (4μM) to the coronary perfusate. Column 3: Recorded 45 
min after the concentration of NS5806 was raised to 8μM. High and low frequency late 
potentials (LP) are apparent in the EG recordings resulting from progressive delay in the 
appearance of the second upstroke of the Epi AP secondary to accentuation of the AP notch. 
Column 4: Recorded 15 min after the addition of the ICa-blocker verapamil (1μM) to the 
coronary perfusate. Column 5: Recorded after 40 min of exposure to verapamil (1μM). Loss 
of the AP dome at Epi1 but not Epi2 gives rise to a phase 2 reentrant beat, which precipitates 
polymorphic VT. Column 6: Recorded 2h after radiofrequency ablation of the epicardial 
surface, and 1h after reintroduction of the provocative agents to the perfusate (in the same 
concentration as before ablation). APs are now recorded from the deep subepicardium- 
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midmyocardium (Mid1, Mid2) instead of the epicardial surface. Ablation markedly 
suppressed the BrS phenotype and abolished all arrhythmic activity. Modified from 168, with 
permission.
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Figure 5. 
Rate and pause-dependence of the J wave in an experimental model and two clinical cases of 
BrS. A: Transmural ECG and transmembrane action potentials (APs) simultaneously 
recorded from a canine right ventricular wedge preparation: Prominent J waves and 
associated AP notches were observed during basic stimulation (S1-S1=4000ms). Premature 
stimulation (S1-S2=300ms) reduced the epicardial AP notch and J wave amplitude. B: Plot 
of epicardial AP notch (□) and J wave (○) amplitude over a range of S1-S2 intervals. 
Restitution of action potential notch amplitude parallels that of the J wave. Reproduced 
from 169 with permission. C: ECG lead V4-V5 recorded from a 34 year-old Chinese man 
with idiopathic ventricular fibrillation, showing prominent J waves that are more 
accentuated after a pause (thick arrows) compared to those (thin arrows) recorded at shorter 
R-R intervals. Note that the amplified J wave after the pause was accompanied by T wave 
inversion (V5), an ECG marker associated with a high risk of ventricular fibrillation. D: A J-
wave-like deflection at the terminal portion of the QRS in a patient with intra-ventricular 
conduction delay. In contrast to the J wave behavior observed in Figure 5C, the end of QRS 
notch observed in this case is tachycardia-dependent. The terminal deflection is attenuated at 
longer the R-R interval (thin arrows) and amplified at the shorter R-R interval (thick 
arrows). Reproduced from 86, with permission.
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Table 1
Features Common to Brugada and Early Repolarization Syndromes and Possible Underlying Mechanisms
BrS ERS Possible Mechanism(s)
Region Associated with highest 
arrhythmic risk
RVOT Inferior myocardium Higher levels of Ito
Male Predominance Yes (>75%) Yes (>80%) Testosterone modulation of ion currents underlying the 
epicardial AP notch
Average age of first event ~35-40 ~36-42
Dynamicity of ECG High High Autonomic modulation of ion channel currents 
underlying early phases of the epicardial AP
VT/VF trigger Short-coupled PVC Short-coupled PVC Phase 2 reentry
Ameliorative response to quinidine Yes Yes Inhibition of Ito and possible vagolytic effect
Ameliorative response to 
Isoproterenol and and milrinone
Yes Yes Increased ICa and faster heart rate
Ameliorative response to cilostazol Yes Yes Increased ICa, reduced Ito and faster heart rate
Ameliorative response to pacing Yes Yes Reduced availability of Ito due to slow recovery from 
inactivation
Vagally-mediated accentuation of 
ECG pattern
Yes Yes Direct effect to inhibit ICa and indirect effect to increase 
Ito (due to slowing of heart rate)
RVOT=right ventricular outflow tract, AP=action potential; PVC=premature ventricular contraction
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Table 2
Gene defects associated with the Early Repolarization (ERS) and Brugada (BrS) syndromes.
Genetic Defects Associated wih ERS
Locus Gene/Protein Ion Channel % of Probands
ERS1 12p11.23 KCNJ8, Kir6.1 ↑IK-ATP
ERS2 12p13.3 CACNA1C, Cav1.2 ↓ ICa 4.1%
ERS3 10p12.33 CACNB2b, Cavβ32b ↓ ICa 8.3%
ERS4 7q21.11 CACNA2D1, Cavá2ä ↓ ICa 4.1%
ERS5 12p12.1 ABCC9, SUR2A ↑ IK-ATP Rare
ERS6 3p21 SCN5A, Nav1.5 ↓ INa Rare
ERS7 3p22.2 SCN10A, Nav1.8 ↓ INa
Genetic Defects Associated with BrS
Locus Gene/Protein Ion Channel % of Probands
BrS1 3p21 SCN5A, Nav1.5 ↓ INa 11-28%
BrS2 3p24 GPD1L ↓ INa Rare
BrS3 12p13.3 CACNA1C, Cav1.2 ↓ ICa 6.6%
BrS4 10p12.33 CACNB2b, Cavβ2b ↓ ICa 4.8%
BrS5 19q13.1 SCN1B, Navβ1 ↓ INa 1.1%
BrS6 11q13-14 KCNE3, MiRP2 ↑ Ito Rare
BrS7 11q23.3 SCN3B, Navβ3 ↓ INa Rare
BrS8 12p11.23 KCNJ8, Kir6.1 ↑ IK-ATP 2%
BrS9 7q21.11 CACNA2D1, Cavá2ä ↓ ICa 1.8%
BrS10 1p13.2 KCND3, Kv4.3 ↑ Ito Rare
BrS11 17p13.1 RANGRF, MOG1 ↓ INa Rare
BrS12 3p21.2-p14.3 SLMAP ↓ INa Rare
BrS13 12p12.1 ABCC9, SUR2A ↑ IK-ATP Rare
BrS14 11q23 SCN2B, Navβ2 ↓ INa Rare
BrS15 12p11 PKP2, Plakophillin-2 ↓ INa Rare
BrS16 3q28 FGF12, FHAF1 ↓ INa Rare
BrS17 3p22.2 SCN10A, Nav1.8 ↓ INa ~16.7%
BrS18 6q HEY2 (transcriptional factor) ↑ INa Rare
BrS19 7p12.1 SEMA3A, Semaphorin ↑ Ito Rare
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Table 3
Risk stratifiers of patients with the J wave Syndromes
Commonly accepted risk factors
    1. Association of ER or BrS pattern with SCD, unexplained syncope, or unexplained family history of SCD170
    2. History of cardiac events or syncope likely due to VT/VF88, 101, 171, 172
    3. Nocturnal agonal respiration173
    4. Spontaneous Type I BrS ECG88, 173
    5. J point or ST segment elevation of 0.2 mV or greater in right precordial leads in the case of BrS, or inferior and infero-lateral leads or 
global leads in the case of ERS.174, 175
    6. Horizontal or downsloping ST segment following the J wave in cases of ERS96, 97, 174, 176
    7. Appearance of distinct and prominent J waves.86
    8. Association of BrS or ER pattern with abbreviated QT intervals.45, 177
    9. Short-coupled extrasystoles36, 178, 179
    10. Transient J wave augmentation or fluctuation of J wave portends a high risk for VF in patients with ER37
    11. Pause-dependent augmentation of J waves that is accompanied by T wave inversion, see Figure 5C)37, 180.
    12. Association of ER with Horizontal or Descending ST segment96
    13. Late potentials on epicardial bipolar electrogram or SAECG82, 181-186
    14. T wave amplitude variability182
    15. Short ventricular refractory period (VRP < 200 ms) in BrS88
    16. Fragmented QRS87, 88, 98, 187
    17. Prolonged QRS duration in BrS188
Proposed new risk stratifiers
    
1
. Increased Tpeak-Tend interval as a marker of dispersion of repolarization189-194
    2. Reduced QT/RR slope195
    3. Augmented ST-elevation during recovery from exercise (vagally-mediated)
    4. High daily fluctuation of SAECG parameters197.
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Table 4
Differential diagnosis of J wave vs. Intra-ventricular conduction defect-mediated notch syndromes. (IVCD)
J wave IVCD-induced end QRS notch
Male Predominance Yes No
Average Age at Initial Presentation Young adults Older adults
Most common Morphology dome-like smooth appearance Relatively sharp appearance
Response to Change in Heart Rate Bradycardia- and pause-dependent augmentation 
of J wave which may be accompanied by T 
wave inversion.
Tachycardia and prematurity-dependent 
augmentation of the notch
Structural Heart Diseases Rare Common History of myocardial infarction and/or 
cardiomyopathy
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Table 5
Device and Pharmacologic Approach to Therapy of the Brugada Syndrome
Devices and Ablation
    ICD99
    Radiofrequency Ablation82, 105, 198-201
    ? Pacemaker102-104
Pharmacologic Approach to Therapy
        Ineffective or Proarrhythmic
        Amiodarone106
        β Blockers106
        Class IC antiarrhythmics
            Flecainide202
            Propafenone203
        ? Disopyramide107
        Class IA antiarrhythmics
            Procainamide204
        Effective for Treatment of Electrical Storms
        β Adrenergic agonists – isoproterenol139, 142, denopamine125, orciprenaline121, 133
        Phosphodiesterase III Inhibitors-cilostazol132
        Effective General Therapy
        Quinidine10, 113-115, 127-129
        Bepridil157
        Cilostazol combined with bepridil150
        Experimental Therapy
        Ito Blockers - cardioselective and ion channel specific
            Quinidine10
            4-aminopyridine10
            Tedisamil205
            AVE0118206
        PDE-3-inhibitors
            Cilostazol – Increase in ICa and inhibition of Ito91, 152
            Milrinone - ICa augmentation91, 152
        Traditional Chinese Medicine
            Dimethyl lithospermate B – Increase in INa due to slowed inactivation
            Wenxin Keli - combined Ito-block and tyramine-like effect110
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